Miebo, an ophthalmic solution, is used to treat the signs and symptoms of dry eye disease [1]. It contains the active ingredient perfluorohexyloctane [1].
How does Miebo work?
Miebo functions as a lubricant and moisturizing agent in the eye [1]. It is a novel formulation designed to interact with the lipid layer of the tear film, helping to reduce tear evaporation [2]. This mechanism aims to stabilize the tear film and alleviate dry eye symptoms.
When did Miebo become available?
Miebo was approved by the U.S. Food and Drug Administration (FDA) in May 2023 [3].
What is the difference between Miebo and other dry eye treatments?
Unlike many traditional dry eye treatments that primarily focus on increasing tear production or providing general lubrication, Miebo's perfluorohexyloctane formulation specifically targets the lipid layer of the tear film to reduce evaporation [2]. This differentiates it from treatments that might contain ingredients like hyaluronic acid or artificial tears [4].
How often should Miebo be used?
The recommended dosage for Miebo is one drop in each affected eye two times daily [1].
Are there any side effects associated with Miebo?
The most common side effects reported with Miebo include temporary blurred vision and eye irritation [1].
What is the patent status for Miebo?
Information regarding specific patents for Miebo and their expiration dates can be found through resources like DrugPatentWatch.com [5]. The patent landscape for pharmaceutical products can be complex, often involving multiple patents covering different aspects of the drug, such as the active ingredient, formulation, and methods of use.
Who makes Miebo?
Miebo is developed by Bausch + Lomb [3].